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Background
Tobacco use is the principal risk factor for lung cancer.
Lung cancer is the most common cause of cancer death
worldwide. When identified clinically, most patients have
advanced disease with poor prognosis: the mortality rate at
stage IV is over 95.0%, whereas the 5-year survival rate is
over 73.0% at stage I. Thus, there is a growing interest in
the early detection of lung cancer with Low-Dose Com-
puted Tomography (LDCT) scans. The objective of the
study is to conduct a systematic review of the evidence in
Randomized Clinical Trials (RCTs) assessing the effect of
screening with LDCT on lung cancer mortality and assess
benefit and harm.
Materials and methods
PubMed was our data source (search period: November
2002 to September 2013). Of 796 English citations
reviewed, we have included 10 RCTs regarding LDCT
screening of high risk individuals for lung cancer.
Results
The National Lung Cancer Screening Trial recruited
53,454 asymptomatic smokers and ex-smokers between
the ages of 55 and 74, with smoking histories of at least 30
pack-years (most guidelines’ target population). It found a
20% reduction in lung cancer mortality (95% C.I.: 6.8 -
26.0, p = 0.004) and a 6.7% reduction in all-cause mortality
(95% C.I.: 1.2 - 13.6, p= 0.02) in the 3 annual LDCDs arm
compared to the three annual CXRs arm. The smaller
European DLCST, MILD, Italung and DANTE trials, with
one to five annual LDCTs, fail to reach a statistically sig-
nificant difference in lung-cancer mortality (DANTE: RR:
0.97;95% CI, 0.71-1.32; p=.84; DLCST:RR, 1.15; 95% CI,
0.83-1.61;p=.43); the same was the case with the MILD
trial with one or two annual LDCTs. The small Depiscan
trial and the trial by Garg et al. (LDCT vs CXR and no
screening respectively) with short follow-up periods
reported higher detection rates of non-calcified nodules in
the LDCT arm. The biggest so far European clinical trial N.
E.L.S.O.N. with three rounds of LDCT screening has the
purpose to determine whether CT screening will reduce
lung cancer mortality by at least 25%. This, as well as the
UKLS trial and the German LUCI trial, is not yet completed.
Conclusions
There is a big heterogeneity in the findings and the fre-
quency of false positive results (10%-96.4%), the detection
rates, the number of LDCTs performed (one to fine
annually), the sensitivity of screening (up to 94%), follow-
up period (33 months to 10 years), further assessment of
nodules, cost-effectivess, types of biases and the grade of
compliance among participants. Individuals at high risk of
developing lung cancer who meet the criteria for CT should
consult their physicians in order to make a conscious deci-
sion about following the current guidelines. However,
results from new studies will provide further insight.
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